ANDA 213240, held by Chartwell Rx. Ethacrynic Acid.
As of Nov 16, 2026, ANDA 213240 (Ethacrynic Acid), held by Chartwell Rx, was first approved by FDA on Oct 19, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 19, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ethacrynic Acid25MG ยท tablet;oral | Ethacrynic Acid | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters